Serina Therapeutics (SER) Stock
Small biotech developing stem cell therapies for aging. Here's the price, business snapshot, and what's worth knowing about Serina Therapeutics in August 2026.
AgeX Therapeutics Inc (ticker: SER) is a small‑cap biotechnology company focused on regenerative medicine and longevity therapies. The business works with pluripotent stem‑cell platforms and related technologies to explore treatments for age‑related conditions and tissue regeneration. As a development‑stage company with a market capitalisation near $52 million, it has limited or no commercial revenues and depends on research progress, clinical milestones, partnerships and financing. Share price moves can be driven by trial results, licensing agreements or funding events, while failed studies, regulatory setbacks or cash shortages can lead to sharp declines. Investors typically evaluate intellectual property, management experience and cash runway when assessing prospects. Given the long timelines, scientific uncertainty and binary outcomes common in biotech, the stock can be highly volatile. This is general educational information, not personal investment advice; suitability depends on an investor’s risk tolerance and time horizon. Values can rise and fall and returns are not guaranteed.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AgeX Therapeutics' stock, indicating confidence in its future growth.
Financial Health
AgeX Therapeutics Inc is facing challenges with low revenue and financial performance indicators.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Milestones Ahead
Trial results and partnerships can act as catalysts, though outcomes are binary and timelines may be long.
Stem‑cell Platform Focus
The company centres on pluripotent cell platforms, offering potential upside alongside scientific and regulatory hurdles.
Small‑cap Considerations
With a market cap under $100m the stock can be volatile and less liquid; suitability depends on your risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.